Featured Articles

Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer

This week Sellas Life Sciences Group announced data from a study of NeuVax (nelipepimut-S) in combination with Herceptin (trastuzumab) in patients with HER2 1+/2+ breast cancer.

[ Read More ]

Fear of Cancer Recurrence in Gynecologic Cancer Survivors: An Overview

Although there are some differences in the results compared with the existing literature, this study found that younger age and shorter interval from treatment was associated with increased FCR

[ Read More ]

Transforming Healthcare Through Research and Reporting

It is imperative that as navigators, we share the work we are doing in our individual institutions to allow for the development of evidence-based best practices.

[ Read More ]